NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

8300	Companies
115014	Keywords
55394	Articles
62493	Press releases

Home
Companies
NanoViricides, Inc.

PRESS RELEASE

published on 09/26/2024 at 12:30, 1 month 25 days ago

NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs
NanoViricides, Inc. obtains right of first refusal for antiviral drug developments from TheraCour Pharma, expands drug portfolio with new MOU and revolutionary nanoviricide technology, including NV-387 for multiple viral infections

NV-387 Antiviral Drugs NanoViricides Inc. TheraCour Pharma Nanoviricide Technology
BRIEF

published on 08/26/2024 at 13:35, 2 months 26 days ago

NanoViricides étudie le NV-387 pour le traitement du MPOX dans le cadre du protocole MEURI de l'OMS

NanoViricides NV-387 Mpox Protocole MEURI OMS
BRIEF

published on 08/26/2024 at 13:35, 2 months 26 days ago

NanoViricides Investigates NV-387 for MPOX Treatment Under WHO's MEURI Protocol

NanoViricides NV-387 Mpox WHO MEURI Protocol
PRESS RELEASE

published on 08/26/2024 at 13:30, 2 months 26 days ago

MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX
NanoViricides, Inc. reports investigating NV-387 for MPOX treatment under WHO MEURI protocol amidst 2024 outbreak. NV-387 shows promise in animal studies for broad-spectrum antiviral use

NanoViricides NV-387 Broad-spectrum Antiviral MPOX Treatment WHO MEURI Protocol
BRIEF

published on 08/19/2024 at 12:35, 3 months 2 days ago

NanoViricides Advances Towards Phase II Trial of NV-387

NanoViricides NV-387 Antiviral Therapy Phase II Trial RSV, COVID, Influenza
BRIEF

published on 08/19/2024 at 12:35, 3 months 2 days ago

NanoViricides avance vers la phase II de l'essai du NV-387

NanoViricides NV-387 Essai De Phase II Thérapie Antivirale VRS, COVID, Grippe
PRESS RELEASE

published on 08/19/2024 at 12:30, 3 months 2 days ago

NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
NanoViricides, Inc. provides update on Phase II clinical trial plans for broad-spectrum antiviral drug candidate NV-387 against RSV, COVID, and Influenza. Potential $12 Billion market. Novel trial design expected

NanoViricides NV-387 Clinical Trial Antiviral Phase II
BRIEF

published on 08/08/2024 at 12:35, 3 months 13 days ago

NanoViricides Updates Clinical Program and Strategy

NV-387 Clinical Trials RSV Treatment Antiviral Nanomedicines Broad-spectrum Antiviral
BRIEF

published on 08/08/2024 at 12:35, 3 months 13 days ago

NanoViricides met à jour son programme clinique et sa stratégie

NV-387 Essais Cliniques Antiviral À Large Spectre Nanomédicaments Antiviraux Traitement Du VRS
PRESS RELEASE

published on 08/08/2024 at 12:30, 3 months 13 days ago

NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics
NanoViricides provides update on clinical program & strategy for novel antiviral drug NV-387, targeting Influenza, COVID, RSV & more. Broad-spectrum potential discussed

NanoViricides NV-387 Clinical Program Antiviral Drug Broad-spectrum

Accesswire

Published on 11/21/2024 at 15:30, 32 minutes ago

CLS Health Opens New Comprehensive Care Clinic in Sugar Creek
Published on 11/21/2024 at 15:05, 57 minutes ago

"The Not-So-Secret Lives of REAL 'Mormon' Wives" - the Eye-Opening New Book From Cedar Fort Publishing & Media - is Now Available for Purchase, Just in Time for Christmas
Published on 11/21/2024 at 15:00, 1 hour 2 minutes ago

2-10 Home Buyers Warranty Makes Triumphant Entry Into Oklahoma Market
Published on 11/21/2024 at 15:00, 1 hour 2 minutes ago

Sound Physicians’ ACO Achieves $22.9M Total Savings in 2023 Medicare Shared Savings Program
Published on 11/21/2024 at 15:00, 1 hour 2 minutes ago

BlackBerry AtHoc "In Process" Finalization for FedRAMP High Authorization

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 15:41, 20 minutes ago

Edison issues report on Murray Income Trust (MUT)
Published on 11/21/2024 at 15:24, 38 minutes ago

Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/21/2024 at 15:23, 39 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Centamin plc
Published on 11/21/2024 at 15:22, 40 minutes ago

Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc
Published on 11/21/2024 at 15:20, 41 minutes ago

Form 8.3 - The Vanguard Group, Inc.: AngloGold Ashanti plc

Les Echos

Published on 11/21/2024 at 06:58, 9 hours 4 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 4 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 4 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 19 hours 54 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 20 hours 42 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE